Impact of lanadelumab on health‐related quality of life in patients with hereditary angioedema in the HELP study

BACKGROUND: An objective of the phase 3 HELP Study was to investigate the effect of lanadelumab on health‐related quality of life (HRQoL) in patients with hereditary angioedema (HAE). METHODS: Patients with HAE‐1/2 received either lanadelumab 150 mg every 4 weeks (q4wks; n = 28), 300 mg q4wks (n = 2...

Descripción completa

Detalles Bibliográficos
Autores principales: Lumry, William R., Weller, Karsten, Magerl, Markus, Banerji, Aleena, Longhurst, Hilary J., Riedl, Marc A., Lewis, Hannah B., Lu, Peng, Devercelli, Giovanna, Jain, Gagan, Maurer, Marcus
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
ORIGINAL ARTICLES
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8247292/
https://www.ncbi.nlm.nih.gov/pubmed/33258114
http://dx.doi.org/10.1111/all.14680

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8247292/
https://www.ncbi.nlm.nih.gov/pubmed/33258114
http://dx.doi.org/10.1111/all.14680

Ejemplares similares